Novel lipid hybrid albumin nanoparticle greatly lowered toxicity of pirarubicin

Molecular Pharmaceutics

Volumn 10, Issue 10, 2013, Pages 3832-3841

  Zhou, Jing ^a   Zhang, Xuanmiao ^a   Li, Mei ^a   Wu, Wenqi ^a   Sun, Xun ^a   Zhang, Ling ^b   Gong, Tao ^a  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Albumin; Nanoparticle; Oleic acid complex; Pirarubicin; Safety evaluation; Toxicity

Indexed keywords

EXCIPIENT; HUMAN SERUM ALBUMIN; NANOPARTICLE; OLEIC ACID; PHOSPHATIDYLCHOLINE; PIRARUBICIN; PIRARUBICIN OLEIC ACID COMPLEX ALBUMIN NANOPARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER INHIBITION; CARDIOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; LIPIDS; MALE; MICE; NANOPARTICLES; OLEIC ACID; RATS; RATS, WISTAR; SARCOMA;

EID: 84888357038     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400303w     Document Type: Article

References (33)

1. Yamamoto, Y.; Nasu, Y.; Saika, T.; Akaeda, T.; Tsushima, T.; Kumon, H. The absorption of pirarubicin instilled intravesically immediately after transurethral resection of superficial bladder cancer. BJU Int. 2000, 86 (7), 802-804.
2. Kawano, K.; Takayama, K.; Nagai, T.; Maitani, Y. Preparation and pharmacokinetics of pirarubicin loaded dehydration.rehydration vesicles. Int. J. Pharm. 2003, 252 (1), 73-79.
3. Majima, H. Exploratory clinical study of 4'-O-tetrahydropyranyl doxorubicin (THP-ADM), phase I. Jpn. J. Cancer Chemother. 1983, 10, 134.
4. Ogawa, M.; Miyamoto, H.; Inigaki, J.; Horikoshi, N.; Ezaki, K.; Inoue, K.; Ikeda, K.; Usui, N.; Nakada, H. Phase I clinical trial of a new anthracycline: 4'-o-tetrahydropyranyl adriamycin. Invest. New Drug 1983, 1 (2), 169-172.
5. Hryniuk, W.; Figueredo, A.; Goodyear, M. In applications of dose intensity to problems in chemotherapy of breast and colorectal cancer. Semin. Oncol. 1987, 3.
6. Wong, H. L.; Bendayan, R.; Rauth, A. M.; Li, Y.; Wu, X. Y. Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles. Adv. Drug Delivery Rev. 2007, 59 (6), 491-504.
7. Cong, W.; Liu, Q.; Chen, X.; Gao, R.; Lu, J.; Wang, Y.; Luo, G. Characterization and pharmacokinetics of a novel pirarubicin liposome powder. Drug Dev. Ind. Pharm. 2010, 36 (10), 1186-1194.
8. Daruwalla, J.; Nikfarjam, M.; Greish, K.; Malcontenti-Wilson, C.; Muralidharan, V.; Christophi, C.; Maeda, H. In vitro and in vivo evaluation of tumor targeting styrene-maleic acid copolymerpirarubicin micelles: Survival improvement and inhibition of liver metastases. Cancer Sci. 2010, 101 (8), 1866-1874.
9. Daruwalla, J.; Greish, K.; Nikfarjam, M.; Millar, I.; Malcontenti-Wilson, C.; Iyer, A. K.; Christophi, C. Evaluation of the effect of SMApirarubicin micelles on colorectal cancer liver metastases and of hyperbaric oxygen in CBA mice. J. Drug Targeting 2007, 15 (7.8), 487-495.
10. Favoulet, P.; Cercueil, J. P.; Faure, P.; Osmak, L.; Isambert, N.; Beltramo, J. L.; Cognet, F.; Krause, D.; Bedenne, L.; Chauffert, B. Increased cytotoxicity and stability of lipiodol.pirarubicin emulsion compared to classical doxorubicin.lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma. Anticancer Drugs 2001, 12 (10), 801-806.
11. Gao, H.; Cao, S.; Chen, C.; Cao, S.; Yang, Z.; Pang, Z.; Xi, Z.; Pan, S.; Zhang, Q.; Jiang, X. Incorporation of lapatinib into lipoprotein-like nanoparticles with enhanced water solubility and antitumor effect in breast cancer. Nanomedicine 2013, No. 0, 1-14.
12. Müller, R. H.; Mäder, K.; Gohla, S. Solid lipid nanoparticles (SLN) for controlled drug delivery: a review of the state of the art. Eur. J. Pharm. Biopharm. 2000, 50 (1), 161-177.
13. Wissing, S.; Kayser, O.; Müller, R. Solid lipid nanoparticles for parenteral drug delivery. Adv. Drug Delivery Rev. 2004, 56 (9), 1257-1272.
14. Joshi, M. D.; Müller, R. H. Lipid nanoparticles for parenteral delivery of actives. Eur. J. Pharm. Biopharm. 2009, 71 (2), 161-172.
15. Kratz, F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J. Controlled Release 2008, 132 (3), 171-183.
16. Westesen, K.; Siekmann, B. Investigation of the gel formation of phospholipid-stabilized solid lipid nanoparticles. Int. J. Pharm. 1997, 151 (1), 35-45.
17. Gao, H.; Yang, Z.; Cao, S.; Xi, Z.; Zhang, S.; Pang, Z.; Jiang, X. Behavior and anti-glioma effect of lapatinib-incorporated lipoproteinlike nanoparticles. Nanotechnology 2012, 23 (43), 435101.
18. Hong, M.; Zhu, S.; Jiang, Y.; Tang, G.; Pei, Y. Efficient tumor targeting of hydroxycamptothecin loaded PEGylated niosomes modified with transferrin. J. Controlled Release 2009, 133 (2), 96-102.
19. Hong, M.; Zhu, S.; Jiang, Y.; Tang, G.; Sun, C.; Fang, C.; Shi, B.; Pei, Y. Novel anti-tumor strategy: PEG-hydroxycamptothecin conjugate loaded transferrin-PEG-nanoparticles. J. Controlled Release 2010, 141 (1), 22-29.
20. Ishida, T.; Harada, M.; Wang, X. Y.; Ichihara, M.; Irimura, K.; Kiwada, H. Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Controlled Release 2005, 105 (3), 305-317.
21. Goldberg, D.; Winfield, D. Diagnostic accuracy of serum enzyme assays for myocardial infarction in a general hospital population. Br. Heart J. 1972, 34 (6), 597.
22. Sobel, B. E.; Shell, W. E. Serum enzyme determinations in the diagnosis and assessment of myocardial infarction. Circulation 1972, 45 (2), 471-482.
23. Smith, A.; Radford, D.; Wong, C.; Oliver, M. Creatine kinase MB isoenzyme studies in diagnosis of myocardial infarction. Br. Heart J. 1976, 38 (3), 225-232.
24. Roberts, R.; Gowda, K.; Ludbrook, P. A.; Sobel, B. E. Specificity of elevated serum MB creatine phosphokinase activity in the diagnosis of acute myocardial infarction. Am. J. Cardiol. 1975, 36 (4), 433-437.
25. Ozer, J. S.; Chetty, R.; Kenna, G.; Palandra, J.; Zhang, Y.; Lanevschi, A.; Koppiker, N.; Souberbielle, B. E.; Ramaiah, S. K. Enhancing the utility of alanine aminotransferase as a reference standard biomarker for drug-induced liver injury. Regul. Toxicol. Pharmacol. 2010, 56 (3), 237-246.
26. Caglar, K.; Kinalp, C.; Arpaci, F.; Turan, M.; Saglam, K.; Ozturk, B.; Komurcu, S.; Yavuz, I.; Yenicesu, M.; Ozet, A. Cumulative prior dose of cisplatin as a cause of the nephrotoxicity of high-dose chemotherapy followed by autologous stem-cell transplantation. Nephrol., Dial., Transplant. 2002, 17 (11), 1931-1935.
27. Jiang, Y.; Jiang, X.; Law, K.; Chen, Y.; Gu, J.; Zhang, W.; Xin, H.; Sha, X.; Fang, X. Enhanced anti-tumor effect of 9-nitro-camptothecin complexed by hydroxypropyl-β-cyclodextrin and safety evaluation. Int. J. Pharm. 2011, 415 (1), 252-258.
28. Higashiyama, M.; Inada, K.; Ohtori, A.; Kakehi, K. NMR analysis of ion pair formation between timolol and sorbic acid in ophthalmic preparations. J. Pharm. Biomed. 2007, 43 (4), 1335-1342.
29. Zhang, X.; Sun, X.; Li, J.; Zhang, X.; Gong, T.; Zhang, Z. Lipid nanoemulsions loaded with doxorubicin-oleic acid ionic complex: characterization, in vitro and in vivo studies. Pharmazie 2011, 66 (7), 496-505.
30. Pontes-Arruda, A. Biological benefits of an oleic acid-rich lipid emulsion for parenteral nutrition. Clin. Nutr. Suppl. 2009, 4 (1), 19-23.
31. Fu, Q.; Sun, J.; Zhang, W.; Sui, X.; Yan, Z.; He, Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anticancer drug delivery. Recent Pat. Anti-Cancer Drug Discovery 2009, 4 (3), 262-272.
32. Yoshimatsu, K.; Kuhara, K.; Itagaki, H.; Aizawa, M.; Yokomizo, H.; Fujimoto, T.; Otani, T.; Osawa, G.; Kobayashi, R.; Ogawa, K. Changes of immunological parameters reflect quality of life-related toxicity during chemotherapy in patients with advanced colorectal cancer. Anticancer Res. 2008, 28 (1B), 373-378.
33. Greish, K.; Nagamitsu, A.; Fang, J.; Maeda, H. Copoly (styrenemaleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity. Bioconjugate Chem. 2005, 16 (1), 230-236.